Furthermore, 36 compounds out of the 45 potential AIs and of the 85 potential ER antagonists were simultaneously considered as both promising AIs as well as ERα antagonists, suggesting that they may act as multi-target compounds in ER+ breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.